Management of BRAF-mutant metastatic colorectal cancer

被引：2
|
作者：
Burge, Matthew [1 ,2 ]
Whitehall, Vicki [2 ,3 ,4 ]
机构：
[1] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[2] Univ Queensland, Brisbane, Qld, Australia
[3] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[4] Pathol Queensland, Brisbane, Qld, Australia
来源：
COLORECTAL CANCER | 2016年 / 5卷 / 04期
关键词：
BRAF; colorectal cancer; metastasis; therapy;
D O I：
10.2217/crc-2016-0012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [21] Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
    Sundar, Raghav
    Hong, David S.
    Kopetz, Scott
    Yap, Timothy A.
    CANCER DISCOVERY, 2017, 7 (06) : 558 - 560
  • [22] Retrospective study of BRAF-mutant metastatic colorectal cancer patients and influence of the mismatch repair efficiency.
    Mais, Laetitia
    Sarrabi, Matthieu
    Desseigne, Francoise
    Guibert, Pierre
    Castillo, Christine
    Foulfoin, Margaux
    Karabajakian, Andy
    De La Fouchardiere, Christelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Bradley, William D.
    Lee, Richard J.
    Schostack, Kathleen
    Simcox, Mary Ellen
    Kopetz, Scott
    Heimbrook, David
    Lestini, Brian
    Bollag, Gideon
    Su, Fei
    CANCER RESEARCH, 2012, 72 (03) : 779 - 789
  • [24] Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
    Kopetz, Scott
    McDonough, Shannon L.
    Morris, Van Karlyle
    Lenz, Heinz-Josef
    Magliocco, Anthony Martin
    Atreya, Chloe Evelyn
    Diaz, Luis A.
    Allegra, Carmen Joseph
    Wang, Stephen E.
    Lieu, Christopher Hanyoung
    Eckhardt, S. Gail
    Semrad, Thomas John
    Kaberle, Kimberly
    Guthrie, Katherine A.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Exploring the best treatment options for BRAF-mutant metastatic colon cancer
    Julien Taieb
    Alexandra Lapeyre-Prost
    Pierre Laurent Puig
    Aziz Zaanan
    British Journal of Cancer, 2019, 121 : 434 - 442
  • [27] Exploring the best treatment options for BRAF-mutant metastatic colon cancer
    Taieb, Julien
    Lapeyre-Prost, Alexandra
    Puig, Pierre Laurent
    Zaanan, Aziz
    BRITISH JOURNAL OF CANCER, 2019, 121 (06) : 434 - 442
  • [28] Treatment patterns of patients with BRAF-mutant metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK Registry)
    Zahn, M. -O.
    Doerfel, S.
    Schnell, R.
    Wolf, T.
    Vehling-Kaiser, U.
    Kruggel, L.
    Jaenicke, M.
    Wetzel, N.
    Marschner, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 129 - 129
  • [29] The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis
    Gelsomino, Fabio
    Casadei-Gardini, Andrea
    Rossini, Daniele
    Boccaccino, Alessandra
    Masi, Gianluca
    Cremolini, Chiara
    Spallanzani, Andrea
    Viola, Massimo Giuseppe
    Garajova, Ingrid
    Salati, Massimiliano
    Elia, Maria Teresa
    Caputo, Francesco
    Santini, Chiara
    Falcone, Alfredo
    Cascinu, Stefano
    Tamburini, Emiliano
    CANCERS, 2020, 12 (04)
  • [30] Comment on: “Exploring the best treatment options for BRAF-mutant metastatic colon cancer”
    Gérard Milano
    Jocelyn Gal
    British Journal of Cancer, 2020, 122 : 1724 - 1725
12345